Literature DB >> 30074565

Prevalence of potential modifiable factors of hypertension in patients with difficult-to-control hypertension.

Nicolette G C Van Der Sande1,2, Peter J Blankestijn2, Frank L J Visseren1, Martine M Beeftink3, Michiel Voskuil3, Jan Westerink1, Michiel L Bots4, Wilko Spiering1.   

Abstract

BACKGROUND: A comprehensive diagnostic evaluation of potential modifiable factors of difficult-to-control hypertension would enable clinicians to target-specific amendable causes. Therefore, we assessed the prevalence of underlying medical conditions, lifestyle factors, and concomitant medication use in an integrated diagnostic evaluation in patients with difficult-to-control hypertension, referred to a tertiary center.
METHODS: The study population consisted of 653 patients referred between 2006 and 2016 for difficult-to-control hypertension to the University Medical Center Utrecht. Difficult-to-control hypertension was defined by not reaching blood pressure (BP) goals despite BP-lowering drug use, or high office BP (>160/100 mmHg) without BP-lowering drug use. Patients were evaluated according to a highly standardized protocol including 24-h ambulatory blood measurements after cessation of BP-lowering drugs, 24-h urine sample, and a isotonic (0.9%) saline infusion test.
RESULTS: In 621 patients (95%) one or more modifiable factors related to hypertension were identified (mean 2.1, SD 1.1). Obesity-related insulin resistance was the most common underlying medical condition which was diagnosed in 130 patients (20%). Primary aldosteronism was diagnosed in 40 patients (6%) and obstructive sleep apnea in 17 patients (3%). Sodium intake was deemed to high (urinary excretion of >6 g/day) in 433 patients (66%). In total, 283 patients (43%) were physical inactive (<30 min/day, during 5 days/week). Oral contraceptive-related hypertension was diagnosed in 10 women (3% of women).
CONCLUSION: In patients with difficult-to-control hypertension there is a high prevalence of potential modifiable factors related to hypertension, highlighting the importance for an integrated diagnostic evaluation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30074565     DOI: 10.1097/HJH.0000000000001885

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Blood pressure control and cardiovascular risk profile in hypertensive patients under specialist care in Argentina: Results from the CHARTER study.

Authors:  Marcos Marín; Jessica Barochiner; Pablo Rodríguez; Nicolás Renna; Carlos Castellaro; Walter Espeche; Alejandro De Cerchio; Mildren Del Sueldo; Sergio Vissani; Judith Zilberman
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09-03       Impact factor: 3.738

2.  Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension.

Authors:  Monique E A M van Kleef; Frank L J Visseren; Jan Westerink; Michiel L Bots; Peter J Blankestijn; Yolanda van der Graaf; Wilko Spiering
Journal:  BMC Endocr Disord       Date:  2020-04-29       Impact factor: 2.763

3.  Assessing Outcomes After Adrenalectomy for Primary Aldosteronism - Early is Accurate: Retrospective Cohort Study.

Authors:  Diederik P D Suurd; Wessel M C M Vorselaars; Dirk-Jan Van Beek; Inne H M Borel Rinkes; Wilko Spiering; Gerlof D Valk; Menno R Vriens
Journal:  Ann Surg       Date:  2022-07-27       Impact factor: 13.787

Review 4.  Fighting Oxidative Stress with Sulfur: Hydrogen Sulfide in the Renal and Cardiovascular Systems.

Authors:  Joshua J Scammahorn; Isabel T N Nguyen; Eelke M Bos; Harry Van Goor; Jaap A Joles
Journal:  Antioxidants (Basel)       Date:  2021-03-02

Review 5.  Recent Development toward the Next Clinical Practice of Primary Aldosteronism: A Literature Review.

Authors:  Yuta Tezuka; Yuto Yamazaki; Yasuhiro Nakamura; Hironobu Sasano; Fumitoshi Satoh
Journal:  Biomedicines       Date:  2021-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.